Effect Of The Promoter Methylation Of Genes SHH And HOXD10 In E Ndometrial Carcinoma And Its Pathological Significances

PurposeTo analyze the promoter methylation status of genes SHH and HOXD10 in endometrial carcinoma and explore its pathological significances.Methods62 endometrial carcinoma samples (including 50 endometroid adenocarcinoma samples and 12 mucinous endometrial carcinoma samples), and 70 control group samples (including 22 simple hyperplasia,29 complex hyperplasia and 19 atypical hyperplasia) were colleceted. All the samples were evaluated for the methylation of SHH, HOXD10, ZNF545, PCDH17 and MEIS1 by methylation-specific PCR and for the protein expression by immunohistochemistry.Results(1)The methylation rate of SHH and HOXD10 in tumor group (82.88%and 69.35%, respectively) was obviously higher than control group (21.43%and 15.71%), p< 0.001. Methylation status of SHH shows relevance to the age of patient (p< 0.02),and methylation status of HOXD10 shows relevance to infiltration depth(p< 0.02), while the methylation was not correlated with the tumor differentiation,size and lymph node metastasis. (2)The IHC staining HOXD10 was ligher in carcinoma group than control group (p< 0.001), and was negatively related to its methylation status (p< 0.05). Compares with endometrial adenocarcinoma, mucinous endometrial carcinoma samples had no staining of HOXD10 and evidently less staining of SHH (p< 0.001 and p< 0.02, respectively).ConclusionsThe promoter of SHH and HOXD10 were hypermethylation in endometrial cancer, which causes SHH and HOXD10 lowly expressed in tissue. Gene expression of SHH and HOXD10 in endometroid adenocarcinoma and mucinous endometrial carcinoma has differences.